IRIS
MAFFEZZINI, MASSIMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.417
AS - Asia 12
SA - Sud America 4
NA - Nord America 2
Totale 6.435
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 6.417
CN - Cina 5
SG - Singapore 5
BR - Brasile 3
US - Stati Uniti d'America 2
VN - Vietnam 2
AR - Argentina 1
Totale 6.435
Salva come PNG Salva come JPEG
Città #
Genova 3.863
Genoa 1.340
Rapallo 729
Vado Ligure 435
Bordighera 50
Ashburn 2
Beijing 1
Guanambi 1
Haiphong 1
Ninh Bình 1
Registro 1
Santa Rosa 1
Singapore 1
São Paulo 1
Totale 6.427
Salva come PNG Salva come JPEG
Nome #
A randomized phase IIb presurgical study of finasteride vs. low-dose flutamide vs. placebo in men with prostate cancer. Efficacy monitored by karyometry. 164
Bladder cell culture on small intestinal submucosa as bioscaffold: Experimental study on engineered urothelial grafts 154
Systemic absorption and pharmacokinetics of single-dose early intravesical mitomycin C after transurethral resection of non-muscle invasive bladder cancer. 150
Adherence to Guidelines among Italian Urologists on Imaging Preoperative Staging of Low-Risk Prostate Cancer: Results from the MIRROR (Multicenter Italian Report on Radical Prostatectomy Outcomes and Research) Study. 144
Developing a five-step training model for transperineal prostate biopsies in a naïve residents’ group: a prospective observational randomised study of two different techniques 142
A Multimodal Perioperative Plan for Radical Cystectomy and Urinary Intestinal Diversion: Effects, Limits and Complications of Early Artificial Nutrition 140
Are referral centers for non-muscle-invasive bladder cancer compliant to EAU guidelines? A report from the vesical antiblastic therapy Italian study. 137
Evaluation of complications and results in a contemporary series of 300 consecutive radical retropubic prostatectomies with the anatomic approach at a single institution 136
Pre-operative assessment of cancer in the elderly (PACE): A comprehensive assessment of underlying characteristics of elderly cancer patients prior to elective surgery 135
Large bladder diverticula: a comparison between laparoscopic excision and endoscopic fulguration 133
Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help - A SIOG surgical task force prospective study. 131
Clinical outcome in testicular sex cord stromal tumors: testis sparing vs. radical orchiectomy and management of advanced disease 130
Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation 130
A Simple Mathematical Approach to Calculate Blood Loss in Radical Prostatectomy 129
Incidence and survival of rare urogenital cancers in Europe. 129
Age Is Predictive of Immediate Postoperative Urinary Continence after Radical Retropubic Prostatectomy 127
Estimates of prostate cancer burden in Italy. 126
A prognostic model including pre- and postsurgical variables to enhance risk stratification of primary mediastinal nonseminomatous germ cell tumors: the 27-year experience of a referral center. 125
"What if…": decisional regret in patients who discontinued active surveillance 124
Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral Center. 120
The impact of prior TURP on radical prostatectomy surgical margins: a multicenter analysis. 117
Postchemotherapy lymphadenectomy in patients with metastatic urothelial carcinoma: long-term efficacy and implications for trial design 116
Multimodal Perioperative Plan for Radical Cystectomy and Intestinal Urinary Diversion. I. Effect on Recovery of Intestinal Function and Occurrence of Complications 115
Interim fluorine-18 fluorodeoxyglucose positron emission tomography for early metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma. 115
Fast-track surgery and technical nuances to reduce complications after radical cystectomy and intestinal urinary diversion with the modified Indiana pouch 113
Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes. 111
Current perioperative management of radical cystectomy with intestinal urinary reconstruction for muscle-invasive bladder cancer and reduction of the incidence of postoperative ileus 111
For wider acceptance of radical cystectomy and extended pelvic lymphadenectomy 110
Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder 109
Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer. 108
Immunohistochemistry to enhance prognostic allocation and guide decision-making of patients with advanced urothelial cancer receiving first-line chemotherapy. 108
Active surveillance in young patients with prostate cancer: the unanswered question 108
Pharmacokinetics and toxicity of an early single intravesical instillation of gemcitabine after endoscopic resection of superficial bladder cancer 105
Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. 103
Feeding Hungry Patients, Even Those Well Nourished 102
Editorial comment on: long-term rates of undetectable psa with initial observation and delayed salvage radiotherapy after radical prostatectomy 102
The clinical use of statistical permutation test methodology: a tool for identifying predictive variables of outcome. 101
Re: Vincent Cloutier, Umberto Capitanio, Laurent Zini, et al. Thirty-Day Mortality after Nephrectomy: Clinical Implications for Informed Consent. Eur Urol 2009;56:998-1005 97
TC Incidence Increasing: Spread the Word 95
Re: Trends in hospital volume and operative mortality for high-risk surgery 95
Integrated gene and miRNA expression analysis of prostate cancer associated fibroblasts supports a prominent role for interleukin-6 in fibroblast activation. 94
Short-Schedule Intravesical Gemcitabine with Ablative Intent in Recurrent Ta–T1, G1–G2, Low- or Intermediate-Risk, Transitional Cell Carcinoma of the Bladder 90
Systemic Absorption and Pharmacokinetics of Single-dose Intravesical Gemcitabine After Transurethral Resection of the Bladder in Non-muscle-invasive Bladder Cancer 90
Focal therapy in urology: kidney cancer 89
Prostatic metastases from testicular nonseminomatous germ cell cancer: two case reports and a review of the literature. 89
Intravesical mitomycin C combined with local microwave hyperthermia in non-muscle-invasive bladder cancer with increased European Organization for Research and Treatment of Cancer (EORTC) score risk of recurrence and progression. 87
High-Risk Prostate Cancer is Worth Further Risk Stratification 87
Peri-operative management of ablative and reconstructive surgery for invasive bladder cancer in the elderly. 87
Paraganglioma of the prostate in a young adult 86
Phase I-II Trial of Weekly Bicalutamide in Men with Elevated Prostate-Specific Antigen and Negative Prostate Biopsies 86
PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial. 85
The magnitude of the problem and the burden of physicians and patient decisions 84
Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer 84
Osteopontin plasma levels does not detect prostate cancer in patientsreferred for diagnostic biopsy 82
Systemic Absorption and Pharmacokinetics of Single-Dose, Post-TURB (Trans-Urethral Resection of Bladder), Intravesical Gemcitabine, in Non-Muscle Invasive Bladder Cancer. 81
Bladder Cancer 76
Intravesical gemcitabine in recurrent superficial bladder carcinoma: preliminary results on ablative efficacy and tolerability. 72
Urinary Diversion and Morbidity After Radical Cystectomy for Bladder Cancer 60
Prognostic Significance of Fluorescent In Situ Hybridisation in the Follow-up of Non-muscle-invasive Bladder Cancer 52
The survival of patients with bone metastases from renal cell carcinoma 50
Response to editorial comment from Dr Todenhöfer and Dr Schwentner to recurrence and progression in patients with non-muscle invasive bladder cancer: prognostic models including multicolor fluorescence in situ hybridization molecular grading. 42
Totale 6.500
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.931
article - articoli 22.617
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 314
Totale 45.862
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021292 0 0 0 0 24 39 15 54 24 71 30 35
2021/2022818 30 83 67 71 23 78 50 162 65 64 41 84
2022/2023856 74 47 3 96 102 146 0 99 142 3 138 6
2023/2024323 22 42 6 39 16 52 14 51 15 11 24 31
2024/2025990 5 84 23 58 150 143 64 152 49 61 110 91
2025/2026403 170 14 109 106 4 0 0 0 0 0 0 0
Totale 6.500